Recent Updates
Recently added Catalysts

SNA-120

Phase 2

Pruritus | Small Molecules | Dermatology |Sienna Biopharmaceuticals, Inc.|Trials Updated: Feb 8, 2019

SNA-120 development status

Highest phase Phase 2
Registered trials 2 across 1 sponsor since Oct 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials2
Total Enrollment281

FDA Designations

No designations recorded

SNA-120 clinical trials

SNA-120 · 2 trials · 3 indications

Phase 2 2
NCT03448081Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With CalcipotrienePruritus
COMPLETED73 Analytics
NCT03322137Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis VulgarisPruritus
COMPLETED208 Analytics
PHASE2COMPLETED
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
Pruritus
NCT0344808173
Unlock trial analytics
PHASE2COMPLETED
Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris
Pruritus
NCT03322137208
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change in Itch Numeric Rating Scale scores (I-NRS) from baseline
week 8

11-point NRS scale used to assess pruritus severity, ranging from 0 (no itching at all) to 10 (worst possible itching)

Change in Itch Numeric Rating Scale scores (I-NRS)
week 1

The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching

Secondary Endpoints

Change in Investigator Global Assessment (IGA) from baseline
week 8
Change in Psoriasis Area Severity Index (PASI) from baseline
week 8
Proportion of subjects (≥ 1 grade change) on IGA scale
week 12
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
SNA-120 + CalcipotrieneACTIVE_COMPARATOR -
Placebo + CalcipotrienePLACEBO_COMPARATOR -
SNA-120 (0.05% )ACTIVE_COMPARATORPegcantratinib Ointment
SNA-120 (0.5%)ACTIVE_COMPARATORPegcantratinib Ointment
VehiclePLACEBO_COMPARATOR -

Interventions

NameTypeDescription
SNA-120DRUGSNA-120 (0.5%) active ointment
PlaceboDRUGVehicle Ointment
CalcipotrieneDRUGCalcipotriene ointment (0.005%)
VehicleDRUGPlacebo ointment to mimic Pegcantratinib ointment
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites20

Inclusion Criteria: * Written informed consent * Stable psoriasis for at least 6 months prior to screening * Chronic pruritus of the psoriasis plaques at least 6 weeks prior to screening * At least moderate baseline overall itch associated with psoriatic plaques * Willing and able to undergo a 4-we...

Countries:United StatesCanada
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Sienna Biopharmaceuticals, Inc. (SNNAQ)Pipeline, catalysts, financials, insiders and newsPruritus disease mapEvery company developing for Pruritus, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with SCompanies A to ZEvery biotech and pharma company we track